Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
To the Editor, Targeting B-cell maturation antigen (BCMA) has transformed the relapsed/refractory multiple myeloma (RRMM) landscape with unprecedented overall survival (OS) outcomes versus standard-of-care triplet regimens. Belantamab mafodotin, an anti-BCMA antibody-drug conjugate, has a multimodal mechanism of action involving minimal immunosuppression and no evidence of induction of T-cell exhaustion [1, 2].
A national nerve was touched last month when a New York City man gunned down four youths after they asked him for $5 in a subway station. The public support for Bernhard Goetz was resounding and overwhelming, national polls showed. That shooting occurred in the middle of a series of similar citizen actions here in Oklahoma. Though the circumstances are different in each of the Oklahoma cases, they share a common thread.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
